Asciminib Enhances Its Treatment Efficacy Synergistically in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation When Combined with a Reduced Dose of Ponatinib, Dasatinib, or Bosutinib, but Not with Nilotinib or Imatinib
Ho Jae Han(Seoul National University), Dennis Dong Hwan Kim(University Health Network), Amirthagowri Ambalavanan(Queen's University), Michael W. Deininger(Versiti Blood Center of Wisconsin), Anthea Travas(University Health Network), Jaeyoon Kim(LG (United States)), Jong‐Won Kim(Samsung Medical Center), Danielle Pyne(University Health Network), Shinya Kimura(Saga University)
Cited by 2
Related Papers
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2010|1k
Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter.
|Molecular Pharmacology|1992|481
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464